Seminal pharmaceutical trials: maintaining masking in analysis
- 1 July 2002
- journal article
- Published by Elsevier in The Lancet
- Vol. 360 (9327) , 100-101
- https://doi.org/10.1016/s0140-6736(02)09436-9
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?BMJ, 2002
- Industry-sponsored clinical research: a double-edged swordThe Lancet, 2001
- The Clinical TrialControlled Clinical Trials, 2001
- Cardiovascular Thrombotic Events in Controlled, Clinical Trials of RofecoxibCirculation, 2001
- Sponsorship, Authorship, and AccountabilityNew England Journal of Medicine, 2001
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotectionThe Lancet, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Blinding during data analysis and writing of manuscriptsControlled Clinical Trials, 1996